Selected research
Industry Research
Dermatomyositis Drug Industry Research Report 2026
Market perspective
The global Dermatomyositis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Dermatomyositis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Dermatomyositis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Dermatomyositis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Dermatomyositis Drug include Novartis AG, Eli Lilly and Company, Pfizer Inc, Octapharma AG, Neovacs SA, MedImmune LLC, Marathon Pharmaceuticals LLC, KPI Therapeutics Inc and Idera Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dermatomyositis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dermatomyositis Drug Market by Company
Novartis AG
Eli Lilly and Company
Pfizer Inc
Octapharma AG
Neovacs SA
MedImmune LLC
Marathon Pharmaceuticals LLC
KPI Therapeutics Inc
Idera Pharmaceuticals Inc
Hope Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Dermatomyositis Drug Segment by Type
Immune Globulin
Dalazatide
Baricitinib
Abatacept
IMO-8400
Others
Dermatomyositis Drug Segment by Application
Hospital
Clinic
Others
Dermatomyositis Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatomyositis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dermatomyositis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatomyositis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dermatomyositis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dermatomyositis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dermatomyositis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immune Globulin
- Dalazatide
- Baricitinib
- Abatacept
- IMO-8400
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Novartis AG
- Eli Lilly and Company
- Pfizer Inc
- Octapharma AG
- Neovacs SA
- MedImmune LLC
- Marathon Pharmaceuticals LLC
- KPI Therapeutics Inc
- Idera Pharmaceuticals Inc
- Hope Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dermatomyositis Drug Market Size (2021-2032)
- 2.2.2 Global Dermatomyositis Drug Sales (2021-2032)
- 2.2.3 Global Dermatomyositis Drug Market Average Price (2021-2032)
- 2.3 Dermatomyositis Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Immune Globulin
- 2.3.3 Dalazatide
- 2.3.4 Baricitinib
- 2.3.5 Abatacept
- 2.3.6 IMO-8400
- 2.3.7 Others
- 2.4 Dermatomyositis Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dermatomyositis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dermatomyositis Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Dermatomyositis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Dermatomyositis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Dermatomyositis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dermatomyositis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dermatomyositis Drug, Product Type & Application
- 3.8 Global Manufacturers of Dermatomyositis Drug, Established Date
- 3.9 Global Dermatomyositis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Dermatomyositis Drug Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Eli Lilly and Company
- 4.2.1 Eli Lilly and Company Company Information
- 4.2.2 Eli Lilly and Company Business Overview
- 4.2.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eli Lilly and Company Dermatomyositis Drug Product Portfolio
- 4.2.5 Eli Lilly and Company Recent Developments
- 4.3 Pfizer Inc
- 4.3.1 Pfizer Inc Company Information
- 4.3.2 Pfizer Inc Business Overview
- 4.3.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Inc Dermatomyositis Drug Product Portfolio
- 4.3.5 Pfizer Inc Recent Developments
- 4.4 Octapharma AG
- 4.4.1 Octapharma AG Company Information
- 4.4.2 Octapharma AG Business Overview
- 4.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Octapharma AG Dermatomyositis Drug Product Portfolio
- 4.4.5 Octapharma AG Recent Developments
- 4.5 Neovacs SA
- 4.5.1 Neovacs SA Company Information
- 4.5.2 Neovacs SA Business Overview
- 4.5.3 Neovacs SA Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Neovacs SA Dermatomyositis Drug Product Portfolio
- 4.5.5 Neovacs SA Recent Developments
- 4.6 MedImmune LLC
- 4.6.1 MedImmune LLC Company Information
- 4.6.2 MedImmune LLC Business Overview
- 4.6.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 MedImmune LLC Dermatomyositis Drug Product Portfolio
- 4.6.5 MedImmune LLC Recent Developments
- 4.7 Marathon Pharmaceuticals LLC
- 4.7.1 Marathon Pharmaceuticals LLC Company Information
- 4.7.2 Marathon Pharmaceuticals LLC Business Overview
- 4.7.3 Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Marathon Pharmaceuticals LLC Dermatomyositis Drug Product Portfolio
- 4.7.5 Marathon Pharmaceuticals LLC Recent Developments
- 4.8 KPI Therapeutics Inc
- 4.8.1 KPI Therapeutics Inc Company Information
- 4.8.2 KPI Therapeutics Inc Business Overview
- 4.8.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 KPI Therapeutics Inc Dermatomyositis Drug Product Portfolio
- 4.8.5 KPI Therapeutics Inc Recent Developments
- 4.9 Idera Pharmaceuticals Inc
- 4.9.1 Idera Pharmaceuticals Inc Company Information
- 4.9.2 Idera Pharmaceuticals Inc Business Overview
- 4.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Idera Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio
- 4.9.5 Idera Pharmaceuticals Inc Recent Developments
- 4.10 Hope Pharmaceuticals Inc
- 4.10.1 Hope Pharmaceuticals Inc Company Information
- 4.10.2 Hope Pharmaceuticals Inc Business Overview
- 4.10.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hope Pharmaceuticals Inc Dermatomyositis Drug Product Portfolio
- 4.10.5 Hope Pharmaceuticals Inc Recent Developments
- 4.11 F. Hoffmann-La Roche Ltd
- 4.11.1 F. Hoffmann-La Roche Ltd Company Information
- 4.11.2 F. Hoffmann-La Roche Ltd Business Overview
- 4.11.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Product Portfolio
- 4.11.5 F. Hoffmann-La Roche Ltd Recent Developments
5 Global Dermatomyositis Drug Market Scenario by Region
- 5.1 Global Dermatomyositis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dermatomyositis Drug Sales by Region: 2021-2032
- 5.2.1 Global Dermatomyositis Drug Sales by Region: 2021-2026
- 5.2.2 Global Dermatomyositis Drug Sales by Region: 2027-2032
- 5.3 Global Dermatomyositis Drug Revenue by Region: 2021-2032
- 5.3.1 Global Dermatomyositis Drug Revenue by Region: 2021-2026
- 5.3.2 Global Dermatomyositis Drug Revenue by Region: 2027-2032
- 5.4 North America Dermatomyositis Drug Market Facts & Figures by Country
- 5.4.1 North America Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dermatomyositis Drug Sales by Country (2021-2032)
- 5.4.3 North America Dermatomyositis Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Dermatomyositis Drug Market Facts & Figures by Country
- 5.5.1 Europe Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dermatomyositis Drug Sales by Country (2021-2032)
- 5.5.3 Europe Dermatomyositis Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Dermatomyositis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dermatomyositis Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dermatomyositis Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dermatomyositis Drug Market Facts & Figures by Country
- 5.7.1 South America Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dermatomyositis Drug Sales by Country (2021-2032)
- 5.7.3 South America Dermatomyositis Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Dermatomyositis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dermatomyositis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dermatomyositis Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dermatomyositis Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Dermatomyositis Drug Sales by Type (2021-2032)
- 6.1.1 Global Dermatomyositis Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Dermatomyositis Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Dermatomyositis Drug Revenue by Type (2021-2032)
- 6.2.1 Global Dermatomyositis Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dermatomyositis Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Dermatomyositis Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dermatomyositis Drug Sales by Application (2021-2032)
- 7.1.1 Global Dermatomyositis Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Dermatomyositis Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Dermatomyositis Drug Revenue by Application (2021-2032)
- 7.2.1 Global Dermatomyositis Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dermatomyositis Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Dermatomyositis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dermatomyositis Drug Value Chain Analysis
- 8.1.1 Dermatomyositis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dermatomyositis Drug Production Mode & Process
- 8.2 Dermatomyositis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dermatomyositis Drug Distributors
- 8.2.3 Dermatomyositis Drug Customers
9 Global Dermatomyositis Drug Analyzing Market Dynamics
- 9.1 Dermatomyositis Drug Industry Trends
- 9.2 Dermatomyositis Drug Industry Drivers
- 9.3 Dermatomyositis Drug Industry Opportunities and Challenges
- 9.4 Dermatomyositis Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst